The present technology detects immune cell activation. In certain embodiments, the system has a polymer block with a reaction chamber having an optically clear light path and fluidic connections to a device having a microcontroller in communication with electromagnets, air pumps, valves, an LED light source, and a photosensor. The polymer block is able to receive a blood sample in media comprising antibody coated beads.

An assay device including a loading zone for a sample that may contain an analyte, an activator in communication with the loading zone from which at least one activator is displaced by presence of the analyte, an amplifier in an inactive state in communication with the activator that becomes activated in the presence of the activator, a biomatrix barrier in communication with the activated amplifier that is degraded or modified by the activated amplifier, and an indicator responsive to the degradation or modification of the biomatrix barrier, which in turn reflects a concentration of the analyte in the sample loaded on the device. The selection of analyte or displacement of the activator by presence of the analyte may occur off-platform and/or may rely on use of non-covalent interactions. The activator may include an enzyme or other reagent that activates the amplifier. Also, associated methods.

Nanoparticulate material suitable for administration to a subject, the nanoparticulate material having bound to its surface: (a) copolymeric steric stabiliser that promotes dispersion of the nanoparticulate material in a liquid, wherein the copolymeric steric stabiliser comprises (i) an anchoring polymer segment having one or more binding groups that bind the copolymeric steric stabiliser to the nanoparticulate material, and (ii) a steric stabilising polymer segment that is different from the anchoring polymer segment, and (b) copolymeric mapping moiety comprising (i) an anchoring polymer segment having one or more binding groups that bind the copolymeric mapping moiety to the nanoparticulate material, (ii) one or more mapping groups comprising an agent that specifically binds to fibroblast activation protein (FAP), and (iii) a coupling polymer segment that is different to the anchoring polymer segment, wherein the coupling polymer segment couples the anchoring polymer segment to the one or more mapping groups.

Disclosed herein are improved methods to assay and quantify enzymatic activity of remodeling enzymes and identifying modulators of remodeling enzyme activity. Methods for performing a nucleosome remodeling assay can comprise steps of contacting a recombinant nucleosome substrate with a remodeling enzyme; binding the recombinant nucleosome substrate to a solid support; contacting the recombinant nucleosome substrate with a cleaving enzyme that recognizes a cleaving enzyme site of the recombinant nucleosome; activating the cleaving enzyme to cleave an exposed cleaving enzyme site on the recombinant nucleosome substrate to produce a cleaved nucleosome fragment; separating the cleaved nucleosome fragment from the solid support; and quantifying an amount of DNA associated with the cleaved nucleosome fragment, wherein the amount of DNA is associated with the nucleosome remodeling activity and/or detecting histones in the cleaved nucleosome fragment.

The disclosed methods are directed to preparing and detecting polypeptides using neutrophil elastase, such as human neutrophil elastase. The polypeptides are optionally denatured, reduced, and/or alkylated before being subjected to a first digestion. A second digestion comprises the use of neutrophil elastase, such as human neutrophil elastase. The prepared fragments are then analyzed chromatographically, electrophoretically, or spectrometrically, or a combination of these methods. The methods are especially useful for the preparation of therapeutic polypeptides for analysis, especially those that are not easily cleaved, such as some bi-specific T-cell engager (BiTE) molecules.

The presently described and claimed disclosure relates to capillary electrophoresis methods for quantifying an intact AAV genome and protein components in an AAV using the same capillary electrophoresis system. The claimed and described approach offers an automated analysis of AAV samples and provides information to determine the AAV empty/full ratio.

A method of isolating ultrashort single-stranded cell-free DNA (uscfDNA) is described as well as methods of using the uscfDNA for detecting biomarkers and diagnosing diseases and disorders.

The present disclosure provides a method of assessing translation efficacy of an mRNA using liquid chromatography-tandem mass spectrometry (LC-MS/MS). The mRNA is first translated into protein either in a cell lysate (cell-free translation; CFT) or inside a cell (cell-based translation; CBT) and analyzed using LC-MS/MS. The method provides advantages such as speed and convenience over traditional immunoassay-based methods of detecting translated proteins. Translation using CBT may be necessary in certain formulations of the mRNA, such as when the mRNA or a mixture of mRNAs is encapsulated inside a lipid nanoparticle.

Provided herein are methods, kits and compositions for detecting an analyte of interest to interrogate spatial gene expression in a sample using templated ligation.